[Per Note Total Price to public(1) Underwriting discounts Proceeds, before expenses, to us (1) Plus accrued interest, if any, from , 2014. We have granted the underwriters an option to purchase up to an additional US$60,000,000 aggregate principal amount of the Notes on the same terms and conditions as set forth above within 30 days of the date of this]
[Prospectus Supplement To Prospectus Dated December 31, 2013 Registration No. 333-192963 Biostar Pharmaceuticals, Inc. 1,650,000 shares of common stock Our shares of common stock are currently traded on the Nasdaq Capital Market under the symbol “BSPM.” On March 7, 2014, the closing sale price of our shares of common stock was $2.97 per share. Risk Factors Investing in our securities]
[Prospectus Supplement To Prospectus Dated December 31, 2013 Registration No. 333-192963 Biostar Pharmaceuticals, Inc. 1,650,000 shares of common stock Our shares of common stock are currently traded on the Nasdaq Capital Market under the symbol “BSPM.” On March 7, 2014, the closing sale price of our shares of common stock was $2.97 per share. Risk Factors Investing in our securities]
[CANADIAN SOLAR INC. INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Use these links to rapidly review the document PROSPECTUS SUPPLEMENT (To Prospectus dated August 13, 2013) 2,778,000 Common Shares Canadian Solar Inc. This is an offering of an aggregate of 2,778,000 common shares, with no par value, of Canadian Solar Inc. Our common shares are traded on the Nasdaq Global]
[This is an offering of an aggregate of 2,600,000 common shares, with no par value, of Canadian Solar Inc. Our common shares are traded on the Nasdaq Global Market, under the symbol "CSIQ." On February 10, 2014, the closing sale price of our common shares on the Nasdaq Global Market was $39.12 per common share. Investing in our common shares]
[This is an offering of an aggregate of 2,600,000 common shares, with no par value, of Canadian Solar Inc. Our common shares are traded on the Nasdaq Global Market, under the symbol "CSIQ." On February 10, 2014, the closing sale price of our common shares on the Nasdaq Global Market was $39.12 per common share. Investing in our common shares]
[PROSPECTUS SUPPLEMENT (To Prospectus dated August 19, 2013) 5,000,000 Shares Seaspan Corporation 8.25% Series E Cumulative Redeemable Perpetual Preferred Shares (Liquidation Preference $25 Per Share) We are offering 5,000,000 of our 8.25% Series E Cumulative Redeemable Perpetual Preferred Shares, par value $0.01 per share, liquidation preference $25.00 per share (the Series E Preferred Shares). Dividends on the Series E Preferred]
[PROSPECTUS SUPPLEMENT (To Prospectus dated August 19, 2013) 5,000,000 Shares Seaspan Corporation 8.25% Series E Cumulative Redeemable Perpetual Preferred Shares (Liquidation Preference $25 Per Share) We are offering 5,000,000 of our 8.25% Series E Cumulative Redeemable Perpetual Preferred Shares, par value $0.01 per share, liquidation preference $25.00 per share (the Series E Preferred Shares). Dividends on the Series E Preferred]
